验证数据展示
经过测试的应用
Positive IF/ICC detected in | HEK-293 cells |
推荐稀释比
Application | Dilution |
---|---|
Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
CL488-24550 targets AMOT in IF/ICC applications and shows reactivity with human samples.
Tested Applications | IF/ICC Application Description |
Tested Reactivity | human |
Immunogen | AMOT fusion protein Ag19784 种属同源性预测 |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Full Name | angiomotin |
Synonyms | KIAA1071, Angiomotin |
Calculated Molecular Weight | 1084 aa, 118 kDa |
Observed Molecular Weight | 80 kDa, 130 kDa |
GenBank Accession Number | BC130294 |
Gene Symbol | AMOT |
Gene ID (NCBI) | 154796 |
RRID | AB_3672768 |
Conjugate | CoraLite® Plus 488 Fluorescent Dye |
Excitation/Emission Maxima Wavelengths | 493 nm / 522 nm |
Form | Liquid |
Purification Method | Antigen affinity purification |
UNIPROT ID | Q4VCS5 |
Storage Buffer | PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
Angiomotin belongs to the motin family of angiostatin binding protein. The encoded protein is expressed predominantly in endothelial cells of capillaries as well as larger vessels of the placenta where it may mediate the inhibitory effect of angiostatin on tube formation and the migration of endothelial cells during the formation of new blood vessels. Most abundant expression was found in placenta and skeletal muscle. AMOT has two isoforms with MW 130 kDa (p130) and 80 kDa (p80). The p130 isoform can interact with F-actin.This antibody recognizes both p130 and p80.
实验方案
Product Specific Protocols | |
---|---|
IF protocol for CL Plus 488 AMOT antibody CL488-24550 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |